These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 27349159)

  • 21. Global patterns of domestic cannabis cultivation: sample characteristics and patterns of growing across eleven countries.
    Potter GR; Barratt MJ; Malm A; Bouchard M; Blok T; Christensen AS; Decorte T; Frank VA; Hakkarainen P; Klein A; Lenton S; Perälä J; Werse B; Wouters M
    Int J Drug Policy; 2015 Mar; 26(3):226-37. PubMed ID: 25582281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthetic Cannabinoids-Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis.
    Fattore L
    Biol Psychiatry; 2016 Apr; 79(7):539-48. PubMed ID: 26970364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic cannabinoid withdrawal: a new demand on detoxification services.
    Macfarlane V; Christie G
    Drug Alcohol Rev; 2015 Mar; 34(2):147-53. PubMed ID: 25588420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthetic cannabinoid JWH-018 and psychosis: an explorative study.
    Every-Palmer S
    Drug Alcohol Depend; 2011 Sep; 117(2-3):152-7. PubMed ID: 21316162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic Cannabinoid Abuse in Adolescents: A Case Series.
    Besli GE; Ikiz MA; Yildirim S; Saltik S
    J Emerg Med; 2015 Nov; 49(5):644-50. PubMed ID: 26293411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation.
    Young AC; Schwarz E; Medina G; Obafemi A; Feng SY; Kane C; Kleinschmidt K
    Am J Emerg Med; 2012 Sep; 30(7):1320.e5-7. PubMed ID: 21802885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.
    Chase PB; Hawkins J; Mosier J; Jimenez E; Boesen K; Logan BK; Walter FG
    Clin Toxicol (Phila); 2016; 54(1):14-9. PubMed ID: 26653952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of drug codes for 26 substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2013 Jan; 78(3):664-6. PubMed ID: 23289157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ["Spice"--synthetic cannabinoids with dangerous effects].
    Personne M; Westerbergh J; Hammer-Pettersen L
    Lakartidningen; 2014 Nov; 111(47):2105-7. PubMed ID: 25386644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative medicine: Ninth Circuit reverses holding on distribution of medical marijuana.
    Zanetti A
    J Law Med Ethics; 1999; 27(4):382-3. PubMed ID: 11067622
    [No Abstract]   [Full Text] [Related]  

  • 31. Care versus convenience: Examining paracetamol overdose in New Zealand and harm reduction strategies through sale and supply.
    Freeman N; Quigley P
    N Z Med J; 2015 Oct; 128(1424):28-34. PubMed ID: 27377019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retail price as an outcome measure for the effectiveness of drug law enforcement.
    Bright DA; Ritter A
    Int J Drug Policy; 2010 Sep; 21(5):359-63. PubMed ID: 20083399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should doctors be allowed to prescribe cannabinoids for pain in Australia and New Zealand?
    Shipton EA; Shipton EE
    Aust N Z J Psychiatry; 2014 Apr; 48(4):310-3. PubMed ID: 24413810
    [No Abstract]   [Full Text] [Related]  

  • 34. Patterns of synthetic cannabinoid use in Australia.
    Barratt MJ; Cakic V; Lenton S
    Drug Alcohol Rev; 2013 Mar; 32(2):141-6. PubMed ID: 23043552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic cannabinoid use: a case series of adolescents.
    Castellanos D; Singh S; Thornton G; Avila M; Moreno A
    J Adolesc Health; 2011 Oct; 49(4):347-9. PubMed ID: 21939863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Public participation in local alcohol regulation: Findings from a survey of New Zealand communities.
    Kypri K; Maclennan B
    Drug Alcohol Rev; 2014 Jan; 33(1):59-63. PubMed ID: 24400703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interim regulated legal market for NPS ('legal high') products in New Zealand: The impact of new retail restrictions and product licensing.
    Wilkins C
    Drug Test Anal; 2014; 6(7-8):868-75. PubMed ID: 24817124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electrooxidation of New Synthetic Cannabinoids: Voltammetric Determination of Drugs in Seized Street Samples and Artificial Saliva.
    Dronova M; Smolianitski E; Lev O
    Anal Chem; 2016 Apr; 88(8):4487-94. PubMed ID: 26905258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dermatological aspects of synthetic cannabinoid addiction.
    Inci R; Kelekci KH; Oguz N; Karaca S; Karadas B; Bayrakci A
    Cutan Ocul Toxicol; 2017 Jun; 36(2):125-131. PubMed ID: 27028361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Legal Highs"--An Emerging Epidemic of Novel Psychoactive Substances.
    Zawilska JB
    Int Rev Neurobiol; 2015; 120():273-300. PubMed ID: 26070762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.